Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensiv
Background: Sickle cell disease is a genetic disorder of haemoglobin (which carries oxygen in red blood cells). The shape of sickle cell-patients' red blood cells is abnormal. Thus, red blood cells can be blocked in small vessels, responsible for painful crises due to a lack of downstream circulation. These crisis (acu
| Condition(s) | Sickle Cell Disease, Glomerular Hyperfiltration, Sickle Cell Nephropathy, Vaso-Occlusive Crises, Acute Chest Syndrome |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Background: Sickle cell disease is a genetic disorder of haemoglobin (which carries oxygen in red blood cells). The shape of sickle cell-patients' red blood cells is abnormal. Thus, red blood cells can be blocked in small vessels, responsible for painful crises due to a lack of downstream circulation. These crisis (acute vaso-occlusive crisis) require strong treatment based on morphine, and often require intensive care.However, treatment is often insufficiently effective. Patient can also experiment acute chest syndrome, a complication of vaso-occlusive crisis, which can be responsible for respiratory failure. In addition, patients with sickle cell disease frequently have kidney damage called sickle cell nephropathy, which in the early stages of the disease is responsible for renal hyperfi |
| Who can participate | Inclusion Criteria: * Patient ≥ 18 years old * Known homozygous sickle cell disease SS, SC, S-beta+, or S-beta0 * Admitted in an intensive care unit * Clinical diagnosis of vaso-occlusive crisis and/or acute chest syndrome * Receiving PCA treatment with morphine * Patient's consent for study participation and/or from a relative if case of patient's incapacity * Affiliation to social protection Exclusion Criteria: * Patient previously included in the study during a previous stay * Injection of iodinated contrast medium outside the scope of the study within 24 hours prior to inclusion, or scheduled within 9 hours following the scheduled time of iohexol injection * Contraindication to iohexol: known or suspected immediate or delayed hypersensitivity, thyrotoxicosis. * Patient undergoing morph |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University Hospital, Tours |
| Locations | Tours, France, France; Créteil, France; Le Mans, France; Nantes, France; Orléans, France; Rennes, France |
| Start date | 2026-03-05 |
| NCT ID | NCT07246265 |
| Official listing | https://clinicaltrials.gov/study/NCT07246265 |